Monthly View Flat View Weekly View Daily View Categories

February 2018

Thursday, February 1, 2018
12:00PM - Understanding Childhood Narcolepsy:  Why it’s more than just a Sleepy Child
Twitter webcast Live from Durham, NC 12pm EST

Narcolepsy is a lifelong neurologic disorder characterized by excessive daytime sleepiness and an imbalance in REM mediated sleep-wake physiology. This imbalance may lead to other signs of narcolepsy, including sleep paralysis, hypnogogic hallucinations, and cataplexy. Childhood onset of disease is common, with onset prior to 15 years of age in one-third of patients, and prior to 5 years of age in 5 percent.1 Despite early onset of symptoms, children often go undiagnosed and untreated for many years, with some studies indicated a median time to diagnosis as long as 10 years.2 Given the vital period for academic and personal development during childhood, a lack of timely diagnosis and treatment may translate into a lifetime of consequences, including poor academic achievement, obesity, social marginalization, and excessive dependency on caregivers. Clearly, the need to identify children early is vital in order to appropriately diagnose and treat narcolepsy.


Friday, February 23, 2018
6:45PM - Non-Statin Therapy for LDL Cholesterol Reduction in Primary and SecondaryPrevention
Hyatt Hill Country, Fredericksburg Ballroom A-D, 9800 Hyatt Resort Drive, San Antonio, Texas

In this program, our faculty James Underberg, MD, MS (Chair); Alan Brown, MD; Peter Jones, MD, and Pamela Morris, MD will focus on the evidence with, and use of, non-statin therapies for LDL-C lowering in the settings of primary and secondary prevention. An interpretation of recently presented and published secondary analyses from cardiovascular outcome trials with non-statin agents will provide lipid specialists with a more comprehensive evaluation of the efficacy and safety of non-statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD). Attendees will also receive an expert assessment of non-statin therapy for primary prevention.  Four interactive challenging cases for lipid specialists with “real-world” patients will enable faculty members to describe best management strategies.